Leap Therapeutics focuses on creating next-generation cancer treatments, most notably sirexatamab (DKN-01), a monoclonal antibody targeting the DKK1 protein that has completed a Phase 2 colorectal cancer trial, and FL-501, aimed at overcoming resistance to immunotherapy by targeting GDF-15. The company’s latest strategic shift pairs its biotech work with a plan to hold digital assets on its balance sheet, making it one of the first life-sciences firms to adopt a crypto treasury model. Management says the blended approach will broaden shareholder value while funding critical clinical research. Investor enthusiasm for this dual strategy sent Leap’s shares up 25 % on the announcement date. A portion of its new capital will buy unspecified cryptocurrencies, while the bulk will advance ongoing and future oncology trials and expand R&D capacity. Winklevoss Capital’s involvement also brings governance changes, including two new board seats and the chairperson role. The company’s strengthened cash position and strategic guidance are intended to accelerate its pipeline toward later-stage trials and potential regulatory submissions.

Total raised

$59M

Funding rounds

1

Latest round

Equity

Latest activity

Oct 2025